March 23, 2020 marked the Biologics Price Competition and Innovation Act transition date, on which nearly 100 drugs previously approved as new drugs under Food, Drug, and Cosmetic Act section 505 transitioned to approved biologics licenses under section 351 of the Public Health Service Act. What are some of the lingering issues associated with the transition and future approval pathways for these drugs and related biosimilar/interchangeable products? The webinar will address transition questions about chemistry, manufacturing, and control requirements; as well as labeling, exclusivity, compounding, and 505(b)(2) applications. The webinar will also discuss regulatory pathways and potential pricing implications for transitioned products and related biosimilar/interchangeable biologic candidates.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


David V. Ceryak, Senior Director, Assistant General Counsel, Regulatory Legal Team, Eli Lilly and Company
Lee Rosebush, Partner, BakerHostetler
Moderated by Catherine M. Cook, Executive Vice President, Drug and Biological Products,  Greenleaf Health, Inc.

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content